Abstract
Vaccinia virus recombinants that express cloned genes encoding antigens of unrelated infectious agents, such as hepatitis B virus1 and human immunodeficiency virus (HIV)2,3, provide a new approach to the development of live vaccines. Although there is evidence that genetically engineered vaccinia viruses have reduced pathogenicity4 a major obstacle to their use as vaccines is that severe complications can occur after vaccination, especially in immunodeficient individuals5,6. We describe here a recombinant vaccinia virus expressing murine interleukin-2 (IL-2) and show that athymic nude mice infected with the recombinant virus resolve the virus infection rapidly whereas mice infected with control virus develop a progressive vaccinal disease. By incorporating the gene for IL-2 in live virus vaccines it may be possible to prevent the severe complications that arise in recipients with an impaired immune system.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Smith, G. L., Mackett, M. & Moss, B. Nature 302, 490–495 (1983).
Chakrabarti, S., Robert-Guroff, M., Wong-Staal, F., Gallo, R. C. & Moss, B. Nature 320, 535–537 (1986).
Hu, S.-L., Kosowski, S. G. & Dalrymple, J. M. Nature 320, 537–540 (1986).
Buller, R. M. L., Smith, G. L., Cremer, K., Notkins, A. L. & Moss, B. Nature 317, 813–815 (1985).
Dick, G. Prog. med. Viro'l. 8, 1–29 (1966).
Redfield, R. R. et al. N. Engl. J. Med. 316, 673–676 (1987).
Smith, K. A. A. Rev. Immun. 2, 319–333 (1984).
Yokota, T. et al. Proc. natn. Acad. Sci. U.S.A 82, 68–72 (1985).
Andrew, M. E., Coupar, B. E. H., Ada, G. L. & Boyle, D. B. Microbial Pathogenesis 1, 443–452 (1986).
Lifson, J. D., Benike, C. J., Mark, D. F., Koths, K. & Engleman, E. G. Lancet i, 698–702 (1984).
Gluckman, J. C., Klatzmann, D. & Montagnier, L. A Rev. Immun. 4, 97–117 (1986).
Gillis, S., Ferm, M. M., Ou, W. & Smith, K. A. J. Immun. 120, 2027–2032 (1978).
Mosmann, T. J. immunol. Meth. 65, 55–63 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ramshaw, I., Andrew, M., Phillips, S. et al. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329, 545–546 (1987). https://doi.org/10.1038/329545a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/329545a0
This article is cited by
-
Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution
Cancer Gene Therapy (2010)
-
Initiation of primary anti-vaccinia virus immunity in vivo
Immunologic Research (2007)
-
Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12
Cancer Gene Therapy (2003)
-
Strategies for designing and optimizing new generation vaccines
Nature Reviews Immunology (2001)
-
Potential for Directing Appropriate Responses to Vaccines by Cytokine Manipulation
Clinical Immunotherapeutics (1996)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
